The Form 4 filing, an SEC report of insider stock trades, was filed on October 30, 2026. The sales took place on October 29. It lists Martine A. Rothblatt as United Therapeutics’ chairperson and CEO.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-29 |
| Date of Latest Transaction | 2026-10-29 |
| Buy/Sell | sell |
| Transaction Count | 9 |
| Shares Transacted | 9,500 |
| Price | $594.78 |
| Total Transaction Value | $5,650,414.51 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-10-30 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. The filing covers nine sale transactions in United Therapeutics (UTHR) stock.
What was the average price of the transaction?
The average sale price was $594.78 per share across the nine transactions, rounded to cents. Prices for each separate sale were not provided.
How did this transaction affect the insider's holdings?
She sold 9,500 shares and reported 324,443 shares owned after the sales. The shares sold made up 2.84% of her shares held before the sales.
What's the total transaction value?
The nine sales totaled $5,650,414.51 after rounding to cents. The unrounded value was $5,650,414.5062.
Are there any special circumstances around this transaction?
The available information includes a reference to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. The reference could come from a checkbox that applies to the whole form. Footnote text was not provided to confirm which sales it covers. The plan’s start date, schedule, and other terms are unknown.
For research purposes only; not investment advice.